Last updated on November 2019

A Phase 1 Study To Evaluate Escalating Doses Of A Vaccine-Based Immunotherapy Regimen For Prostate Cancer (PrCa VBIR)

Brief description of study

The study will evaluate the safety, pharmacokinetics and pharmacodynamics of increasing doses of a vaccine-based immunotherapy regimen for patients with prostate cancer.

Clinical Study Identifier: NCT02616185

Find a site near you

Start Over

Smilow Cancer Hospital at Yale-New Haven

New Haven, CT United States
  Connect »